NCT06911528 Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
| NCT ID | NCT06911528 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 709 participants |
| Start Date | 2024-01-30 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 709 participants in total. It began in 2024-01-30 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sentinel Lymph Node Biopsy (SLNB) is a common surgical treatment for breast cancer and a primary method for assessing the pathological status of axillary lymph nodes. Precise intraoperative detection of sentinel lymph nodes during surgery assists in timely evaluation of axillary lymph node pathology and helps in formulating further treatment strategies. Touch imprint cytology (TIC) is one of the most commonly used intraoperative detection techniques. The new intraoperative cellular detection technology, EndoScell Scanner (ES), uses an improved real-time miniaturized fluorescence microscopy system for image acquisition. The ultra-high-resolution images obtained can reach the cellular level. In previous studies, the accuracy and sensitivity of this technology for intraoperative detection of sentinel lymph nodes were comparable to imprint cytology, but it is much more rapid. The detection technology uses fluorescein sodium and methylene blue as fluorescent dyes, which is non-invasive and also non-consumptive of tissue samples. This study involves patients scheduled for sentinel lymph node biopsy and aims to evaluate the clinical application value of the EndoScell Scanner (ES) for intraoperative assessment of the pathological status of sentinel lymph nodes through a prospective self-controlled study. To avoid the potential impact of methylene blue on the ES detection technology, we will use mitoxantrone as a new dye for sentinel lymph node tracing in this study. The primary study objective is to compare the accuracy of the ES detection technology in assessing sentinel lymph node status, using paraffin pathology examination as the gold standard. The primary endpoint is the accuracy of the ES technology. Secondary endpoints include the image quality score of the ES detection, the learning curve of the surgeons, and the time required for detection.
Eligibility Criteria
Inclusion Criteria: * Age 18 years and older (inclusive) * Female * Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ * Scheduled for sentinel lymph node biopsy * Capable of and willing to provide informed consent Exclusion Criteria: * Patients with a confirmed allergy to methylene blue or sodium citrate tracers * Pregnant or lactating women * Patients unwilling to participate in the clinical study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06911528 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06911528 currently recruiting?
Yes, NCT06911528 is actively recruiting participants. Contact the research team at elwin1020@163.com for enrollment information.
Where is the NCT06911528 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06911528 clinical trial?
NCT06911528 is sponsored by Fudan University. The trial plans to enroll 709 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.